Toxidermie lichénoïde à l’imatinib (Glivec®)

Roux, Christian; Boisseau‐Garsaud, Anne‐Marie; Saint-Cyr, I.; Helenon, R.; Quist, D.; Delaunay, C.

doi:10.1016/s0151-9638(04)93669-1

Cited by 23 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our patients presented a lichenoid eruption similar to that described by Roux et al 14 at 1–3 months after starting imatinib therapy. Histopathological findings in all skin biopsy specimens were similar and consistent with a lichenoid drug reaction.…”

Section: Clinical Summary: Indications and Dose Of Imatinib Time Desupporting

confidence: 83%

Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect

Dalmau

Peramiquel

Puig

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

True leuconychia results from a structural abnormality of the nail plate. It is thought to be due to a defect in keratinization with persistence of keratohyaline granules and air trapping within the nail. 5 Our patient presents with true transverse leuconychia of her thumbnails and fingernails which resolved spontaneously during the third trimester of both her pregnancies. The leuconychia decreased in intensity from the thumb to the little finger on both hands and was also associated with transverse yellow bands, most prominent on her thumbnails. Neither phenomenon is readily explained. The menstrual cycle has previously been reported as a cause of transverse leuconychia. 4 The onset of our patient's leuconychia with the commencement of her menses and its 'disappearance' and subsequent 'reappearance' during and following each pregnancy also implies a hormonal influence. The exact aetiology of her leuconychia remains unknown. No similar cases have been reported to date.

show abstract

Section: Clinical Summary: Indications and Dose Of Imatinib Time Desupporting

confidence: 83%

Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect

Dalmau

Peramiquel

Puig

et al. 2006

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Cutaneous lichenoid eruption associated with imatinib is a rare adverse event [12]. Two of the four reported cases of lichenoid eruption due to imatinib involved the buccal mucosa and started 8 -12 weeks after the first adminitration [13].…”

Section: Discussionmentioning

confidence: 99%

Cross Skin Reactivity to Tyrosine Kinase Inhibitors in a Patient with Chronic Myelogenous Leukemia

Broshtilova¹,

Balabanova²

2013

JCT

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKI) targeting the bcr-abl protein, c-kit and the platelet-derived growth factor receptors, are significant part of the pathogenic therapy of chronic myelogenous leukemia. A broad spectrum of cutaneous side effects has been described with the clinical use of imatinib mesylate, ranging from various acute rashes to toxic epidermal necrolysis. Herein, a case of cross skin toxicity to TKI in a patient with chronic myelogenous leukemia is presented. In the course of imatinib mesylate therapy the patient developed a grade 4 diffuse lichenoid drug eruption. Six months after switching to nilotinib, hyperpigmented macules and patches spread over his trunk and extremities. To date, few cases of cross skin reactivity to imatinib and nilotinib have been described, none of which showing different clinical phenotypes. Further understanding of the underlying mechanisms and leading to the development of skin rashes from different class of TKI is important to highlight new drug targets and modify the current therapies to a level of maximal efficacy.

show abstract

“…In patients treated with imatinib, rashes other than non‐specific maculopapular eruption have rarely been reported. Lichenoid reaction, 4 erosive oral lichen, psoriasiform eruption, purpura, or ulceration have also been reported 3 . Severe/life‐threatening cutaneous effects are very rare and are high‐dose related, 1,3 often leading to drug withdrawal.…”

mentioning

confidence: 99%